Anthropic has launched Claude Science, an AI platform aimed at scientific research and pharmaceutical drug discovery. According to NDTV, the company unveiled the tool for use in scientific research, while Yahoo Tech and Pharmaceutical Technology describe it as an AI-driven pharma research and development tool.
MIT Technology Review, in its daily newsletter The Download, reported that Anthropic announced the product at an event for pharmaceutical executives, biotech founders, and researchers. MIT Technology Review calls Claude Science the company's newest flagship product.
The move signals a deeper push by Anthropic into the life sciences. Pharmaceutical Technology frames the launch in the context of big tech companies increasingly eyeing expansion into the wider healthcare and life sciences space.
The timing drew notice. Benzinga characterized the launch as Anthropic "going all in on drug discovery just as pharma stops talking about AI" — suggesting the company is committing to the sector at a moment when some in the industry have grown quieter about the technology's promise.
Drug discovery is notoriously slow and expensive, with candidate molecules often taking years to move from the lab toward clinical testing. Tools that help researchers sift through scientific literature, analyze data, and generate hypotheses could, in principle, compress parts of that timeline — though the sources here do not detail Claude Science's specific capabilities or results.
Why it matters: Anthropic is staking a flagship product on one of the hardest and highest-stakes applications of AI, testing whether the technology can deliver real value in pharmaceutical research even as industry enthusiasm cools.